Obesity Featured Articles

  1. Ophthalmology Patient Engagement And Retention: Point-Of-Need Execution 4/6/2026

    Dropout in retinal trials is often a logistical failure. Reducing travel burden and bringing specialized care to the patient can slash attrition rates and secure critical trial timelines.

  2. When Your Protocol Includes Ocular Endpoints 4/6/2026

    Standardizing ocular endpoint execution reduces participant dropout and eliminates data variability. Specialized oversight secures clinical timelines and ensures high-quality, submission-ready data.

  3. What Patients Are Asking For In Clinical Trials 4/6/2026

    Global insights show how travel demands, uneven compensation, and overlooked caregiver burden undermine trial participation — making flexible, patient-centered approaches essential.

  4. Putting Clinical Trial Needs Right In Patients' Pockets 4/6/2026

    Managing study tasks across multiple tools increases burden for participants. A unified mobile experience simplifies workflows, reduces mental load, and helps patients stay engaged.

  5. Technology Fragmentation Is One Of The Biggest Hidden Risks In Clinical Trials 4/6/2026

    Reclaim your research day by reducing manual data entry. Learn how connecting operational and financial workflows eases administrative burdens and supports site sustainability.

  6. Real-World Evidence Revisited 4/6/2026

    Explore how the latest regulatory updates transform real-world data into a credible evidentiary pathway. Learn the new standards for data reliability and hybrid study design.

  7. General Wellness Isn't A Vibe Anymore: What The 2026 FDA Update Means 4/6/2026

    The FDA’s 2026 guidance has put an end to "wellness by disclaimer." Learn how new standards for wearables and apps impact study design, participant safety, and the evolving ethical role of the IRB.

  8. Clinical Decision Support Software: Clear Expectations For Research Oversight 4/6/2026

    The FDA’s 2026 CDS guidance signals a shift to settled policy. IRBs must now demand greater transparency regarding automation bias and clinician independence to accurately assess study risk.

  9. The FDA's Final BIMO "Processes And Practices" Guidance 4/6/2026

    Gain a clear roadmap for investigators, sponsors, and IRBs. This shift toward transparency replaces regulatory guesswork with predictable standards for every partner in the research ecosystem.

  10. What Does The FDA's 2025 Safety Reporting Guidance Mean For You? 4/6/2026

    New FDA guidance aligns IND safety reports with unanticipated problems, shifting the focus from administrative definitions to proactive participant protection and trial integrity.